Cytokinetics, Incorporated
CYTKNASDAQHealthcare● Active
$67.90
$-3.58(-5.01%)
Market Cap$8.4B
P/E Ratio—
52W High$80.2
52W Low$31.99
Cytokinetics, Incorporated (CYTK) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CYTK · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($784.96M) | ($589.53M) | ($526.24M) | ($388.95M) | ($215.31M) |
| Depreciation & Amort. | $10.13M | $9.53M | $11.89M | $5.81M | $2.28M |
| Stock-Based Comp. | $0.00M | $97.84M | $72.06M | $47.85M | $26.83M |
| Change in Working Capital | ($35.63M) | $35.66M | $3.09M | ($24.70M) | $8.46M |
| Net Cash from Operations | ($510.01M) | ($395.89M) | ($414.33M) | ($299.52M) | ($142.52M) |
| Investing Activities | |||||
| Capital Expenditure | ($24.81M) | ($3.91M) | ($1.42M) | ($11.34M) | ($48.87M) |
| Purchases of Investments | ($1063.17M) | ($1293.42M) | ($635.21M) | ($855.39M) | ($525.04M) |
| Sales of Investments | $1109.65M | $744.23M | $875.88M | $604.59M | $426.14M |
| Net Cash from Investing | $16.67M | ($553.10M) | $239.25M | ($262.13M) | ($147.78M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $490.95M | ($9.62M) | ($0.86M) | $334.66M | $0.00M |
| Net Cash from Financing | $524.46M | $930.61M | $221.32M | $516.17M | $319.98M |
| Free Cash Flow | |||||
| Free Cash Flow | ($534.82M) | ($399.80M) | ($415.75M) | ($310.85M) | ($191.39M) |
| FCF Margin %(computed) | -607.48% | — | — | -328.64% | -271.76% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Cytokinetics, Incorporated data
About Cytokinetics, Incorporated (CYTK) Cash Flow Statement
Cytokinetics, Incorporated generated operating cash flow of ($0.51B) and free cash flow of ($0.53B) for 2025 — a FCF margin of -607.48%. Capital expenditure was ($0.02B).
Frequently asked questions
CYTK · 4 questionsCytokinetics, Incorporated generated free cash flow of ($0.53B) for 2025, down 33.8% year-over-year.
CYTK free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10